Altogether, these results demonstrate that anti-TNFRSF14 treatment improved therapeutic efficacy of anti-PD-L1 in vivo and TNFRSF14 is a potential target for combination ICB strategy with anti-PD-L1 in GBM (Fig. 6J). This evidence concerns the gene CD274 and glioblastoma.